Literature DB >> 30104344

S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit.

Chao Liu1, Cheng-Wu Zhang2,3, Shun Qiang Lo1, Seok Ting Ang1, Katherine Chee Meng Chew1,3, Dejie Yu1, Bing Han Chai3, Bobby Tan1, Fai Tsang1,3, Yee Kit Tai1,4, Bryce Wei Quan Tan1, Mui Cheng Liang1, Hwee Tong Tan5, Jia Ying Tang1, Mitchell Kim Peng Lai6, John Jia En Chua1,7,8, Maxey Ching Ming Chung5, Sanjay Khanna1,7, Kah-Leong Lim1,3,7,9, Tuck Wah Soong10,3,7,11.   

Abstract

Elevated iron deposition has been reported in Parkinson's disease (PD). However, the route of iron uptake leading to high deposition in the substantia nigra is unresolved. Here, we show a mechanism in enhanced Fe2+ uptake via S-nitrosylation of divalent metal transporter 1 (DMT1). While DMT1 could be S-nitrosylated by exogenous nitric oxide donors, in human PD brains, endogenously S-nitrosylated DMT1 was detected in postmortem substantia nigra. Patch-clamp electrophysiological recordings and iron uptake assays confirmed increased Mn2+ or Fe2+ uptake through S-nitrosylated DMT1. We identified two major S-nitrosylation sites, C23 and C540, by mass spectrometry, and DMT1 C23A or C540A substitutions abolished nitric oxide (NO)-mediated DMT1 current increase. To evaluate in vivo significance, lipopolysaccharide (LPS) was stereotaxically injected into the substantia nigra of female and male mice to induce inflammation and production of NO. The intranigral LPS injection resulted in corresponding increase in Fe2+ deposition, JNK activation, dopaminergic neuronal loss and deficit in motoric activity, and these were rescued by the NO synthase inhibitor l-NAME or by the DMT1-selective blocker ebselen. Lentiviral knockdown of DMT1 abolished LPS-induced dopaminergic neuron loss.SIGNIFICANCE STATEMENT Neuroinflammation and high cytoplasmic Fe2+ levels have been implicated in the initiation and progression of neurodegenerative diseases. Here, we report the unexpected enhancement of the functional activity of transmembrane divalent metal transporter 1 (DMT1) by S-nitrosylation. We demonstrated that S-nitrosylation increased DMT1-mediated Fe2+ uptake, and two cysteines were identified by mass spectrometry to be the sites for S-nitrosylation and for enhanced iron uptake. One conceptual advance is that while DMT1 activity could be increased by external acidification because the gating of the DMT1 transporter is proton motive, we discovered that DMT1 activity could also be enhanced by S-nitrosylation. Significantly, lipopolysaccharide-induced nitric oxide (NO)-mediated neuronal death in the substantia nigra could be ameliorated by using l-NAME, a NO synthase inhibitor, or by ebselen, a DMT1-selective blocker.
Copyright © 2018 the authors 0270-6474/18/388365-14$15.00/0.

Entities:  

Keywords:  DMT1; S-nitrosylation; dopaminergic neurons; iron deposition; motoric defects; nitric oxide

Mesh:

Substances:

Year:  2018        PMID: 30104344      PMCID: PMC6596170          DOI: 10.1523/JNEUROSCI.3262-17.2018

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

1.  Site-specific analysis of protein S-acylation by resin-assisted capture.

Authors:  Michael T Forrester; Douglas T Hess; J Will Thompson; Rainbo Hultman; M Arthur Moseley; Jonathan S Stamler; Patrick J Casey
Journal:  J Lipid Res       Date:  2010-11-02       Impact factor: 5.922

2.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

3.  Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function.

Authors:  Nadia Hubert; Matthias W Hentze
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

4.  A fluorometric assay for the measurement of nitrite in biological samples.

Authors:  T P Misko; R J Schilling; D Salvemini; W M Moore; M G Currie
Journal:  Anal Biochem       Date:  1993-10       Impact factor: 3.365

5.  S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds.

Authors:  J S Stamler; D I Simon; J A Osborne; M E Mullins; O Jaraki; T Michel; D J Singel; J Loscalzo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

6.  Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture.

Authors:  Michael T Forrester; J Will Thompson; Matthew W Foster; Leonardo Nogueira; M Arthur Moseley; Jonathan S Stamler
Journal:  Nat Biotechnol       Date:  2009-05-31       Impact factor: 54.908

7.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging.

Authors:  Luigi Zecca; Antonella Stroppolo; Alberto Gatti; Davide Tampellini; Marco Toscani; Mario Gallorini; Giuseppe Giaveri; Paolo Arosio; Paolo Santambrogio; Ruggero G Fariello; Erdem Karatekin; Mark H Kleinman; Nicholas Turro; Oleh Hornykiewicz; Fabio A Zucca
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

8.  Pars compacta of the substantia nigra modulates motor activity but is not involved importantly in regulating food and water intake.

Authors:  G K Hodge; L L Butcher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

9.  Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein.

Authors:  Scott Ayton; Peng Lei; Dominic J Hare; James A Duce; Jessica L George; Paul A Adlard; Catriona McLean; Jack T Rogers; Robert A Cherny; David I Finkelstein; Ashley I Bush
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

10.  Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway.

Authors:  G Weiss; B Goossen; W Doppler; D Fuchs; K Pantopoulos; G Werner-Felmayer; H Wachter; M W Hentze
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  6 in total

1.  Microglia activation induces oxidative injury and decreases SIRT3 expression in dopaminergic neuronal cells.

Authors:  De-Qi Jiang; Yan-Jiao Ma; Yong Wang; Hai-Xiao Lu; Shu-Hui Mao; Shi-Hua Zhao
Journal:  J Neural Transm (Vienna)       Date:  2019-04-19       Impact factor: 3.575

2.  Desferrioxamine Ameliorates Lipopolysaccharide-Induced Lipocalin-2 Upregulation via Autophagy Activation in Primary Astrocytes.

Authors:  Juntao Cui; Yu Yuan; Jun Wang; Ning Song; Junxia Xie
Journal:  Mol Neurobiol       Date:  2022-01-18       Impact factor: 5.590

Review 3.  Inflaming the Brain with Iron.

Authors:  Pamela J Urrutia; Daniel A Bórquez; Marco Tulio Núñez
Journal:  Antioxidants (Basel)       Date:  2021-01-06

4.  Hepcidin Promoted Ferroptosis through Iron Metabolism which Is Associated with DMT1 Signaling Activation in Early Brain Injury following Subarachnoid Hemorrhage.

Authors:  Hongxia Zhang; Robert Ostrowski; Dengzhi Jiang; Qing Zhao; Yidan Liang; Xudong Che; Jun Zhao; Xiang Xiang; Wang Qin; Zhaohui He
Journal:  Oxid Med Cell Longev       Date:  2021-12-27       Impact factor: 6.543

Review 5.  Empirical evidence for biometal dysregulation in Parkinson's disease from a systematic review and Bradford Hill analysis.

Authors:  Amr H Abdeen; Benjamin G Trist; Kay L Double
Journal:  NPJ Parkinsons Dis       Date:  2022-06-27

Review 6.  Opioid Modulation of Neuronal Iron and Potential Contributions to NeuroHIV.

Authors:  Bradley Nash; Elena Irollo; Renato Brandimarti; Olimpia Meucci
Journal:  Methods Mol Biol       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.